Screener
Altimmune ALT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 130,221,154 and 110,882,735 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 13 | 11 |
| Additional paid-in capital | 961,244 | 879,292 |
| Accumulated deficit | (672,046) | (649,483) |
| Accumulated other comprehensive loss, net | (5,224) | (4,928) |
| Total stockholders’ equity | 283,987 | 224,892 |
| Total liabilities and stockholders’ equity | $335,630 | $279,929 |
Item 1. Financial Statements
FAQ
- What is Altimmune's total equity?
- Altimmune (ALT) reported total equity of $283.99M in Q1 2026.
- How has Altimmune's total equity changed year-over-year?
- Altimmune's total equity increased by 99.8% year-over-year, from $142.16M to $283.99M.
- What is the long-term trend for Altimmune's total equity?
- Over 5 years (2020 to 2025), Altimmune's total equity has grown at a -0.1% compound annual growth rate (CAGR), from $225.88M to $224.89M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Altimmune's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude